Market Summary
Affimed N.V. (AFMD): Are the Stars Lining Up for Investors?
Affimed NV (AFMD) unveiled how its immunological therapy has helped treat Hodgkin’s lymphoma. Even though the news only concerns four patients, it was well-received by investors. On April 13, AFMD shares were worth $ 9.89. The stock had gained more than 24% during the week.
